<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.1 20050630//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Breast Cancer Res</journal-id><journal-title>Breast Cancer Research</journal-title><issn pub-type="ppub">1465-5411</issn><issn pub-type="epub">1465-542X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">bcr654</article-id><article-id pub-id-type="pmid">14580260</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Cytoplasmic p21<sup><italic>WAF1/CIP1 </italic></sup>expression is correlated with HER-2/ <italic>neu </italic>in breast cancer and is an independent predictor of prognosis</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Winters</surname><given-names>Zo&#x000eb; E</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib id="A2" contrib-type="author"><name><surname>Leek</surname><given-names>Russell D</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib id="A3" contrib-type="author"><name><surname>Bradburn</surname><given-names>Mike J</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib id="A4" contrib-type="author"><name><surname>Norbury</surname><given-names>Chris J</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib id="A5" contrib-type="author"><name><surname>Harris</surname><given-names>Adrian L</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib></contrib-group><aff id="I1"><label>1</label>University Department of Surgery, Bristol Royal Infirmary, University of Bristol, UK</aff><aff id="I2"><label>2</label>Cancer Research UK Tumour Pathology Group, University of Oxford, Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford, UK</aff><aff id="I3"><label>3</label>Cancer Research UK Medical Statistics Group, Centre for Statistics in Medicine, Institute of Health Sciences, Oxford, UK</aff><aff id="I4"><label>4</label>Cancer Research UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK</aff><pub-date pub-type="ppub"><year>2003</year></pub-date><pub-date pub-type="epub"><day>3</day><month>10</month><year>2003</year></pub-date><volume>5</volume><issue>6</issue><fpage>R242</fpage><lpage>R249</lpage><ext-link ext-link-type="uri" xlink:href="http://ccforum.com/content/5/6/R242"/><history><date date-type="received"><day>9</day><month>6</month><year>2003</year></date><date date-type="rev-request"><day>30</day><month>7</month><year>2003</year></date><date date-type="rev-recd"><day>29</day><month>8</month><year>2003</year></date><date date-type="accepted"><day>2</day><month>9</month><year>2003</year></date></history><copyright-statement>Copyright &#x000a9; 2003 Winters et al., licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.</copyright-statement><abstract><sec><title>Background</title><p>HER-2 (c-erbB2/Neu) predicts the prognosis of and may influence treatment responses in breast cancer. HER-2 activity induces the cytoplasmic location of p21<sup><italic>WAFI</italic>/<italic>CIPI </italic></sup>in cell culture, accompanied by resistance to apoptosis. p21<sup><italic>WAFI</italic>/<italic>CIPI </italic></sup>is a cyclin-dependent kinase inhibitor activated by p53 to produce cell cycle arrest in association with nuclear localisation of p21<sup><italic>WAFI</italic>/<italic>CIPI</italic></sup>. We previously showed that higher levels of cytoplasmic p21<sup><italic>WAFI</italic>/<italic>CIPI </italic></sup>in breast cancers predicted reduced survival at 5 years. The present study examined HER-2 and p21<sup><italic>WAFI</italic>/<italic>CIPI </italic></sup>expression in a series of breast cancers with up to 9 years of follow-up, to evaluate whether <italic>in vitro </italic>findings were related to clinical data and the effect on outcome.</p></sec><sec sec-type="methods"><title>Methods</title><p>The CB11 anti-HER2 monoclonal antibody and the DAKO Envision Plus system were used to evaluate HER-2 expression in 73 patients. p21<sup><italic>WAFI</italic>/<italic>CIPI </italic></sup>staining was performed as described previously using the mouse monoclonal antibody Ab-1 (Calbiochem, Cambridge, MA, USA).</p></sec><sec><title>Results</title><p>HER-2 was evaluable in 67 patients and was expressed in 19% of cases, predicting reduced overall survival (<italic>P </italic>= 0.02) and reduced relapse-free survival (<italic>P </italic>= 0.004; Cox regression model). HER-2-positive tumours showed proportionately higher cytoplasmic p21<sup><italic>WAFI</italic>/<italic>CIPI </italic></sup>staining using an intensity distribution score (median, 95) compared with HER-2-negative cancers (median, 47) (<italic>P </italic>= 0.005). There was a much weaker association between nuclear p21<sup><italic>WAFI</italic>/<italic>CIPI </italic></sup>and HER-2 expression (<italic>P </italic>= 0.05), suggesting an inverse relationship between nuclear p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>and HER-2.</p></sec><sec><title>Conclusion</title><p>This study highlights a new pathway by which HER-2 may modify cancer behaviour. HER-2 as a predictor of poor prognosis may partly relate to its ability to influence the relocalisation of p21<sup><italic>WAFI</italic>/<italic>CIPI </italic></sup>from the nucleus to the cytoplasm, resulting in a loss of p21<sup><italic>WAFI</italic>/<italic>CIPI</italic></sup>tumour suppressor functions. Cytoplasmic p21<sup><italic>WAFI</italic>/<italic>CIPI </italic></sup>may be a surrogate marker of functional HER-2 <italic>in vivo</italic>.</p></sec></abstract><kwd-group><kwd>CDK inhibitor</kwd><kwd>immunohistochemistry</kwd><kwd>phosphatidylinositol-3 kinase/protein kinase <italic>B</italic></kwd><kwd>prognostic markers</kwd></kwd-group></article-meta></front><body><sec><title>Introduction</title><p>HER-2 is one of four Erb B family-type I receptor tyrosine kinases and is the preferred dimerisation partner for the epidermal growth factor receptor [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. The Erb B receptors are important in normal development and in human cancer. HER-2, independent of its own ligand, activates other Erb B receptors to increase their ligand affinity and to amplify biological responses. HER-2 plays a key role in activating cytoplasmic signalling through the phosphatidylinositol-3 kinase (PI-3K)/protein kinase <italic>B </italic>(Akt) and mitogen-activated protein kinase pathways to influence transcription of nuclear genes [<xref ref-type="bibr" rid="B2">2</xref>-<xref ref-type="bibr" rid="B4">4</xref>]. Activation of PI-3K/Akt is involved in cell proliferation and confers resistance to apoptosis [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>]. Breast cancer is associated with deregulated expression of HER-2, detectable as HER-2 amplification or protein overexpression identified in 10&#x02013;40% of tumours [<xref ref-type="bibr" rid="B7">7</xref>]. HER-2 expression is indicative of poor prognosis and may predict tumour responses to hormone therapy and chemotherapy.</p><p>Cell cycle progression is regulated by cyclin-dependent kinases (CDKs) associated with cyclin proteins. p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1</sup>, a downstream target of p53, is a CDK inhibitor that re-enforces p53-mediated G1 and G2 arrest following genotoxic insults, to facilitate DNA repair [<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B11">11</xref>]. The integrity of G1 and G2 checkpoints requires the nuclear localisation of p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>[<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>]. Recent evidence including subcellular fractionation suggests that p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>can localise in the cytoplasm in cancer tissues and cell lines, where it inhibits apoptosis by binding and inhibiting the apoptosis signal-regulating kinase 1 [<xref ref-type="bibr" rid="B13">13</xref>-<xref ref-type="bibr" rid="B17">17</xref>]. Such an anti-apoptotic function in breast cancers could underlie the association between cytoplasmic p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>and poor prognosis [<xref ref-type="bibr" rid="B17">17</xref>]. Upregulation of p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>occurs through PI-3K/Akt signalling, and may involve insulin-like growth factors, p53-dependent pathways or HER-2 expression [<xref ref-type="bibr" rid="B18">18</xref>-<xref ref-type="bibr" rid="B20">20</xref>]. A HER-2-overexpressing breast cancer cell line transcriptionally upregulates p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>and has been shown to produce its cytoplasmic localisation through a mechanism whereby Akt binds and phosphorylates p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>in its nuclear localisation signal [<xref ref-type="bibr" rid="B21">21</xref>]. <italic>In vivo </italic>HER-2 expression may involve changes in the subcellular localisation of p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>to influence the outcome in breast cancer.</p><p>We previously found that breast cancers with higher levels of cytoplasmic p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>predicted reduced overall survival (OS) and relapse-free survival (RFS), with correlation between cytoplasmic p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>and p53 expression on immunohistochemistry [<xref ref-type="bibr" rid="B17">17</xref>]. Recent <italic>in vitro </italic>findings demonstrated a direct influence of HER-2 on cytoplasmic p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1</sup>. This influence prompted us to investigate HER-2 expression in a retrospective series of breast cancers with p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1</sup>staining by immunohistochemistry and a further 4 years of patient follow-up [<xref ref-type="bibr" rid="B21">21</xref>]. We are not aware of any other study to date examining subcellular p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>expression in relation to HER-2 immunoreactivity.</p></sec><sec sec-type="methods"><title>Patients and methods</title><sec><title>Patients</title><p>The study included 73 patients aged 32&#x02013;80 years (median, 55 years) with primary infiltrating carcinoma diagnosed between 1989 and 1992 at the John Radcliffe Hospital. The eligibility criteria were histological diagnosis of breast carcinoma, level one or complete axillary lymph node dissection, no distant metastases and unilateral tumour. Forty-nine (67%) cases were node-negative and 24 (33%) cases were node-positive (N1-mobile ipsilateral or N2-fixed ipsilateral).</p><p>Clinicopathological subgroups were analysed according to the Nottingham Prognostic Index (NPI). They were divided into good, moderate and poor prognostic groups as previously described, with a modification that included no assessment of the internal mammary lymph nodes [<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B23">23</xref>]. Seventeen nongraded nonductal cancers were not included in the NPI groups.</p><p>Adjuvant treatment groups comprised tamoxifen (16 node-negative patients, 14 node-positive patients), cyclophosphamide/methotrexate/5-fluorouracil (six node-negative patients, six node-positive patients), and both tamoxifen plus cyclophosphamide/methotrexate/5-fluorouracil (two node-negative patients, four node-positive patients). Twenty-five node-negative women received no adjuvant treatment.</p><p>The median duration of follow-up was 110 months (range, 46&#x02013;144 months) among patients who were alive at the date of their last visit. Tumour samples were collected shortly after surgery and were fixed in buffered formalin for 24&#x02013;48 hours at room temperature. Tumours were classified according to Azzopardi [<xref ref-type="bibr" rid="B24">24</xref>]. Invasive ductal carcinomas were graded by the modified Bloom's grading system described by Elston and Ellis [<xref ref-type="bibr" rid="B25">25</xref>]. The oestrogen receptor (ER) status was determined using an ELISA assay (Abbott-ERICA; Abbott Laboratories, Maidenhead, UK). Tumours were classified as ER-positive if oestradiol binding exceeded 10 fmol/mg cytosolic protein.</p></sec><sec><title>Immunohistochemistry</title><p>HER-2 immunostaining was performed using the mouse monoclonal anti-HER-2 antibody (RTU-CB11) (NovaCastra/ Vector, Newcastle upon Tyne, UK), and the DAKO Envision Plus HRP system (K4006; DAKO, Ely, Cambridgeshire, UK). Formalin-fixed paraffin sections of breast cancer tissue were baked, dewaxed and rehydrated prior to a peroxidase block (0.1%, v/v hydrogen peroxide) and an incubation in 10% v/v normal goat serum. The primary antibody and horseradish peroxide-labelled polymer were used as per the DAKO Envision kit, followed by 3,3-diaminobenzidine and counterstaining with haematoxylin before mounting.</p><p>HER-2 expression was scored according to the degree and the proportion of membrane staining [<xref ref-type="bibr" rid="B26">26</xref>]. HER-2 expression was negative for a score of 0 or 1+. A score of 0 was defined as no staining or membrane staining in less than 10% of tumour cells. A score of 1+ comprised faint or partly-stained membranes in more than 10% of tumour tissue. Overexpression of c-erbB2 was scored as 2+, defined as weak to moderate complete membrane staining in more than 10% of tumour cells. A score of 3+ was interpreted as strong, complete membrane staining in more than 10% of tumour. This was analysed in the Department of Clinical Laboratory Sciences (by RDL).</p><p>p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>immunoreactivity was evaluated using the mouse monoclonal antibody Ab-1 (Calbiochem, Cambridge, MA, USA) at 0.5 &#x003bc;g/ml. Biotinylated goat anti-mouse IgG (DAKO, Glostrup, Denmark) secondary antibody was used at 15 &#x003bc;g/ml. The Strept ABC Duet kit (DAKO, Denmark) was used for p21<sup><italic>WAF</italic>1/<italic>CIP </italic></sup>detection [<xref ref-type="bibr" rid="B17">17</xref>]. Immunostaining was assessed using a Laborlux microscope (Leitz, Wetzlar, Germany) at 400&#x000d7; overall magnification with a field diameter of 0.46 mm. p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1</sup>immunoreactivity was assessed as the degree of staining intensity and the proportion of cells with p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>in the nucleus and in the cytoplasm, which was graded semiquantitatively to produce an intensity distribution score (IDS) for each localisation [<xref ref-type="bibr" rid="B17">17</xref>]. Calculation of the IDS was performed as follows: IDS (maximum score 300) = 1 &#x000d7; per cent of weakly stained cells + 2 &#x000d7; per cent of moderately stained cells + 3 &#x000d7; per cent of strongly stained cells. Average IDS values were determined by examination of 10 fields [<xref ref-type="bibr" rid="B17">17</xref>].</p></sec><sec><title>Statistical analysis</title><p>The association between HER-2 and patient characteristics was assessed using the Mann&#x02013;Witney test for continuous variables and the chi-squared test for categorical factors. The relationship between HER-2 and the subcellular localisation of p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>was analysed using the Mann&#x02013;Witney U test, with the p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>IDS used as a continuous variable. Analyses of survival data were performed using the log-rank test and the Cox regression model, with survival curves computed using the Kaplain&#x02013;Meier method.</p><p>For both HER-2 and p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>markers univariate and multivariate analyses were performed, the latter adjusting for the NPI score and the treatment received (tamoxifen/ chemotherapy/no treatment). As the NPI is based on nodal involvement, on tumour size and on grade, patients with histologies for whom grade is undefined ('other' cancers) were excluded from the regression analyses. Thirteen patients (all either ductal carcinoma, lobular carcinoma or mixed histology) had no grade information recorded in the data and one patient had no tumour size recorded. These patients were included in the analysis using multiple imputation methods [<xref ref-type="bibr" rid="B27">27</xref>] to estimate the missing values.</p><p>The hazard ratios were derived from the average effect across 10 augmented datasets, with the confidence intervals and significance tests taking into account the uncertainty of the imputations. The multiple imputation was performed by the MICE library within the S-Plus 2000 Guide to Statistics Volumes 1 and 2 (MathSoft, Seattle, WA, USA), and all other analyses were performed using the STATA version 7 software (STATA Corporation, College Station, TX, USA) [<xref ref-type="bibr" rid="B28">28</xref>].</p></sec></sec><sec><title>Results</title><sec><title>HER-2 expression and association with clinicopathologic factors</title><p>HER-2 immunoreactivity was evaluable in 67 (92%) cases, and scored positively in 13 (19%) cases (Fig. <xref ref-type="fig" rid="F1">1</xref>) using scoring of 2+ and 3+ as indicative of HER-2 protein overexpression. Tumours with HER-2 scores of 0 or 1+ were assessed as negative. HER-2 expression was analysed in relation to clinicopathologic criteria (Table <xref ref-type="table" rid="T1">1</xref>), with a significant association of HER-2 positivity with young age (&#x02264; 50 years) (<italic>P </italic>= 0.03) and with ER-negative (&#x02264; 10 fmol/mg) tumours (<italic>P </italic>= 0.05).</p></sec><sec><title>Association of HER-2 with subcellular localisation of p21<sup><italic>WAF1/CIP1</italic></sup></title><p>p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>expression measured as an IDS was analysed in the nucleus and in the cytoplasm in relation to HER-2 expression (Fig. <xref ref-type="fig" rid="F1">1</xref>). Nuclear p21<sup><italic>WAFI</italic>/<italic>CIP</italic>1 </sup>was higher in HER-2-negative tumours with a median IDS of 7.3 (range, 0&#x02013;88.5), compared with a median IDS of 2.3 (range, 0&#x02013;37.5) in HER-2-positive breast cancers (<italic>P </italic>= 0.05) (Fig. <xref ref-type="fig" rid="F2">2</xref>). Cytoplasmic p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>staining was significantly higher in HER-2-positive cancers with a median IDS of 95 (range, 12.5&#x02013;154.5; <italic>P </italic>= 0.005), compared with HER-2-negative tumours with a median IDS of 47 (range, 0&#x02013;134.6) (Fig. <xref ref-type="fig" rid="F2">2</xref>).</p><p>These results suggest that HER-2-positive tumours showed an increase in cytoplasmic p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>of 50 IDS units, compared with a decrease of 5 IDS units for nuclear p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1</sup>. Despite proportionately lower nuclear p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>levels on IDS, the HER-2-associated increase is far greater in terms of cytoplasmic immunoreactivity. This suggests that the association between cytoplasmic p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>and HER-2 positivity is stronger than for nuclear p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1</sup>.</p></sec><sec><title>Relationship of clinicopathological factors to prognosis and the predictive potential of HER-2 and p21<sup><italic>WAF1/CIP1 </italic></sup>expression</title><p>At 9 years, disease relapses were seen in 33 patients (22 of 48 node-negative patients and 11 of 25 node-positive patients); 30 women died from breast carcinoma. The 9-year RFS and OS were 52% and 61%, respectively. Poor prognostic factors such as the presence of lymph node metastases, high tumour grade, large tumour size and negative ER status were all associated with a lower percentage of patients remaining disease-free (RFS) and alive (OS) at 9 years (data not shown). The 5-year OS of the NPI subgroups were 67% (95% confidence interval, 19&#x02013;95%) for the good prognostic group, 78% (95% confidence interval, 61&#x02013;88%) for the moderate prognostic group and 40% (95% confidence interval, 12&#x02013;67%) for the poor prognostic group, respectively.</p><p>Univariate and multivariate analyses were used to investigate possible relationships between patient survival data and HER-2 expression, and the subcellular distribution of p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>(Table <xref ref-type="table" rid="T2">2</xref>). Univariate analysis showed that HER-2 was significantly associated with a decreased OS (<italic>P </italic>= 0.05) and a decreased RFS (<italic>P </italic>= 0.02) (Table <xref ref-type="table" rid="T2">2</xref> and Fig. <xref ref-type="fig" rid="F3">3</xref>). Cytoplasmic p21<sup><italic>WAF</italic>1/<italic>CIP </italic></sup>was associated with a decreased OS and a decreased RFS on univariate analysis (<italic>P </italic>= 0.03) (Table <xref ref-type="table" rid="T2">2</xref>). The multivariate analysis was adjusted for the NPI and treatment groups (no treatment, tamoxifen, other) (Table <xref ref-type="table" rid="T2">2</xref>). Multivariate analysis demonstrated the independent prognostic significance of cytoplasmic p21<sup><italic>WAF</italic>1/<italic>CIP </italic></sup>and HER-2 in relation to OS and RFS, while nuclear p21<sup><italic>WAF</italic>1/<italic>CIP </italic></sup>was not a prognosticator in this study.</p></sec></sec><sec><title>Discussion</title><p>HER-2 enhances cancer cell growth, and a number of <italic>in vitro </italic>studies have highlighted mechanisms to explain its oncogenic potential [<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B29">29</xref>-<xref ref-type="bibr" rid="B31">31</xref>]. The relevance of these mechanisms <italic>in vivo </italic>requires further investigation. Analysis of HER-2 expression in breast cancer is important in the interpretation of patient prognosis and treatment response. In this study, the immunohistochemical detection of HER-2 was in keeping with the reported frequency of protein expression in breast cancers. Despite controversy surrounding the relative value of immunohistochemistry and fluorescence <italic>in situ </italic>hybridisation to evaluate HER-2 overexpression, a recent study has shown good concordance for both tests [<xref ref-type="bibr" rid="B32">32</xref>].</p><p>HER-2 positivity independently predicted prognosis in this group of breast cancers, and was associated with lack of ER expression (Tables <xref ref-type="table" rid="T1">1</xref> and <xref ref-type="table" rid="T2">2</xref>, and Fig. <xref ref-type="fig" rid="F3">3</xref>). Mechanisms underpinning the association of HER-2 with ER-negative tumours need to be determined, with <italic>in vitro </italic>evidence indicating a negative regulation of <italic>HER2 </italic>transcription by steroid hormones [<xref ref-type="bibr" rid="B29">29</xref>]. Clinical relevance of these pathways may underlie hormone resistance in HER-2-expressing breast cancers [<xref ref-type="bibr" rid="B30">30</xref>].</p><p>HER-2 potentiates ligand-induced intracellular signalling by targeting the Akt oncoprotein that mediates cytoplasmic PI-3K signalling [<xref ref-type="bibr" rid="B21">21</xref>]. Through this mechanism, HER-2 and Akt have been shown to block apoptosis <italic>in vitro </italic>by regulating p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>and by enhancing p53 degradation [<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B31">31</xref>]. HER-2 increases p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>expression to inhibit the mitotic CDC2 kinase and to block Taxol-induced apoptosis [<xref ref-type="bibr" rid="B19">19</xref>]. Through an alternative anti-apoptotic pathway, HER-2 induces cytoplasmic p21<sup><italic>WAF</italic>1/<italic>CIP </italic></sup>[<xref ref-type="bibr" rid="B21">21</xref>]. Immunofluorescence and subcellular fractionation have previously demonstrated cytoplasmic p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>in cell lines characterised by transformation, anchorage independence and anti-apoptosis [<xref ref-type="bibr" rid="B13">13</xref>-<xref ref-type="bibr" rid="B16">16</xref>].</p><p>Predominant cytoplasmic p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>has been detected immunohistochemically in breast tumours and in ovarian tumours [<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B17">17</xref>]. Previous studies of breast carcinoma have reported the exclusive nuclear localisation of p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>[<xref ref-type="bibr" rid="B33">33</xref>-<xref ref-type="bibr" rid="B35">35</xref>]. In our study, cytoplasmic p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>staining was evident as previously reported [<xref ref-type="bibr" rid="B33">33</xref>,<xref ref-type="bibr" rid="B36">36</xref>,<xref ref-type="bibr" rid="B37">37</xref>] and was based on the method of microwave antigen retrieval (Fig. <xref ref-type="fig" rid="F1">1b</xref>) using an alkaline buffer (Tris-buffered saline/EDTA, pH 9.0), rather than the acidic citrate buffer (pH 6.0) [<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B34">34</xref>,<xref ref-type="bibr" rid="B35">35</xref>]. This series of breast cancers shows an important association between HER-2 and increased cytoplasmic p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>to substantiate <italic>in vitro </italic>findings (Figs <xref ref-type="fig" rid="F1">1</xref> and <xref ref-type="fig" rid="F2">2</xref>) [<xref ref-type="bibr" rid="B21">21</xref>]. An inverse association between the HER-2 breast tumours and nuclear p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>further implies the ability of HER-2 to mislocalise p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1</sup>. Nuclear p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>is required to preferentially inhibit cyclin/CDK complexes to ensure DNA repair and growth suppression of transformed cells. This process is determined by a carboxyterminal nuclear localisation signal, while mechanisms underlying nuclear export of p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>remain to be determined. <italic>In vitro</italic>, active phosphorylated Akt binds p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>and phosphorylates threonine 145 in the nuclear localisation signal to produce cytoplasmic p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1</sup>[<xref ref-type="bibr" rid="B21">21</xref>]. In a preliminary series of five breast cancers, immunohistochemical detection of phosphorylated Akt was associated with p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>in both the nucleus and the cytoplasm, suggesting an association with HER-2 activation [<xref ref-type="bibr" rid="B21">21</xref>]. This implies that the relationship between HER-2 and the subcellular localisation of p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>is not exclusive <italic>in vitro </italic>and <italic>in vivo</italic>, but reflects a preferential cytoplasmic localisation of p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1</sup>.</p><p>Further <italic>in vivo </italic>studies are required to establish the significance of phosphorylated Akt in relation to HER-2 and subcellular localisation of p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1</sup>, with future possibilities that immunodetection of phosphorylated p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>may imply activation of this pathway. Clinical relevance of HER-2-expressing tumours with cytoplasmic p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>is emphasised by the independent prognostic significance of both parameters. Prognostic significance of cytoplasmic p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1</sup>at 5 years retains its predictive potential for OS and RFS at 9 years. The combined evaluation of cytoplasmic p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>and HER-2 positively did not increase prognostic significance in this study, due to limited patient numbers in the respective subsets. As previously reported, nuclear p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>expression was generally low and provided no prognostic information [<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B33">33</xref>,<xref ref-type="bibr" rid="B35">35</xref>]. Future studies will be required to address what are the best markers.</p><p>The biological implications of cytoplasmic p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>with respect to the ability to assemble and inhibit cyclin/CDK complexes and to bind apoptosis signal-regulating kinase 1 require further investigation. Studies in cell culture suggest a loss of p53 and growth suppressor function, with inhibition of apoptosis. Subcellular localisation of p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>may have relevance underlying mechanisms of HER-2 drug resistance, with the potential for cytoplasmic p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1</sup>-expressing breast tumours to have increased chemoresistance or hormone resistance. Small patient numbers precluded a separate analysis of treatment relapses in cytoplasmic p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1</sup>-expressing tumours. The potential to define and modify this pathway through Herceptin inhibition of HER-2 or through Iressa inhibition of HER-1 could influence downstream targets of the pathways such as Akt and p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>[<xref ref-type="bibr" rid="B38">38</xref>]. The ability of HER-2 to dysregulate p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1</sup>, a key target of p53, is highly relevant in the context of p53 wild-type cancers, in which growth suppression and apoptosis may be inhibited through mislocalisation of p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1</sup>.</p></sec><sec><title>Conclusion</title><p>These presented findings indicate that HER-2 expression may influence tumour outcome through a mechanism regulating the subcellular localisation of p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>to produce a cytoplasmic distribution resulting in a loss of its tumour suppressor functions. Cytoplasmic p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>predicts poor prognostic tumours and may have a role in HER-2-mediated drug resistance, with the potential for future therapeutic manipulation by Herceptin. Cytoplasmic p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>may conceivably be a surrogate marker for HER-2 signalling <italic>in vivo </italic>to classify clinical subgroups of patients most likely to benefit from Herceptin, such that Herceptin inhibition of the pathway could relocate p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>to the nucleus. A cytoplasmic to nuclear relocalisation of p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>could be a useful biological endpoint to analyse the potential efficacy of Herceptin. Other growth factor pathways involving insulin have recently been implicated in Herceptin resistance, suggesting biological modifications of the Herceptin response [<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B39">39</xref>]. Increasingly, there is a rationale for identifying biological markers of drug responsiveness.</p></sec><sec><title>Competing interests</title><p>None declared.</p></sec><sec><title>Abbreviations</title><p>Akt = protein kinase <italic>B</italic>; CDK = cyclin-dependent kinases; ELISA = enzyme-linked immunosorbent assay; ER = oestrogen receptor; IDS = intensity distribution score; NPI = Nottingham Prognostic Index; OS = overall survival; PI-3K = phosphatidylinositol-3 kinase; RFS = relapse-free survival.</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>ZE Winters and RD Leek contributed equally to this work. This work was supported by Cancer Research UK and the Nuffield Foundation (Fellowship to ZEW).</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hynes</surname><given-names>NE</given-names></name><name><surname>Horsch</surname><given-names>K</given-names></name><name><surname>Olayioye</surname><given-names>MA</given-names></name><name><surname>Badache</surname><given-names>A</given-names></name></person-group><article-title>The ErbB receptor tyrosine family as signal integrators</article-title><source>Endocr Relat Cancer</source><year>2001</year><volume>8</volume><fpage>151</fpage><lpage>159</lpage><pub-id pub-id-type="pmid">11566606</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>M&#x000e9;nard</surname><given-names>S</given-names></name><name><surname>Tagliabue</surname><given-names>E</given-names></name><name><surname>Campiglio</surname><given-names>M</given-names></name><name><surname>Pupa</surname><given-names>SM</given-names></name></person-group><article-title>Role of HER2 gene overexpression in breast carcinoma</article-title><source>J Cell Physiol</source><year>2000</year><volume>182</volume><fpage>150</fpage><lpage>162</lpage><pub-id pub-id-type="pmid">10623878</pub-id><pub-id pub-id-type="doi">10.1002/(SICI)1097-4652(200002)182:2&#x0003c;150::AID-JCP3&#x0003e;3.0.CO;2-E</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marshall</surname><given-names>CJ</given-names></name></person-group><article-title>Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation</article-title><source>Cell</source><year>1995</year><volume>80</volume><fpage>179</fpage><lpage>185</lpage><pub-id pub-id-type="pmid">7834738</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>J</given-names></name><name><surname>Grammer</surname><given-names>TC</given-names></name><name><surname>Lemon</surname><given-names>KP</given-names></name><name><surname>Kazlauskas</surname><given-names>A</given-names></name><name><surname>Blenis</surname><given-names>J</given-names></name></person-group><article-title>PDGF-and insulin-dependent pp70S6k activation mediated by phosphatidylinositol-3-OH kinase</article-title><source>Nature</source><year>1994</year><volume>370</volume><fpage>71</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">8015612</pub-id><pub-id pub-id-type="doi">10.1038/370071a0</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Downward</surname><given-names>J</given-names></name></person-group><article-title>Mechanisms and consequences of activation of protein kinase B/Akt</article-title><source>Curr Opin Cell Biol</source><year>1998</year><volume>10</volume><fpage>262</fpage><lpage>267</lpage><pub-id pub-id-type="pmid">9561851</pub-id><pub-id pub-id-type="doi">10.1016/S0955-0674(98)80149-X</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Da Ha</surname><given-names>SR</given-names></name><name><surname>Brunet</surname><given-names>A</given-names></name><name><surname>Greenberg</surname><given-names>ME</given-names></name></person-group><article-title>Cellular survival: a play in three Akts</article-title><source>Genes Dev</source><year>1999</year><volume>13</volume><fpage>2905</fpage><lpage>2927</lpage><pub-id pub-id-type="pmid">10579998</pub-id><pub-id pub-id-type="doi">10.1101/gad.13.22.2905</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Slamon</surname><given-names>DJ</given-names></name><name><surname>Clark</surname><given-names>GM</given-names></name><name><surname>Wong</surname><given-names>SG</given-names></name><name><surname>Levin</surname><given-names>WJ</given-names></name><name><surname>Ulrich</surname><given-names>A</given-names></name><name><surname>McGuire</surname><given-names>WL</given-names></name></person-group><article-title>Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene</article-title><source>Science</source><year>1987</year><volume>235</volume><fpage>177</fpage><lpage>182</lpage><pub-id pub-id-type="pmid">3798106</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kastan</surname><given-names>MB</given-names></name><name><surname>Onyekwere</surname><given-names>O</given-names></name><name><surname>Sidransky</surname><given-names>D</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Craig</surname><given-names>RW</given-names></name></person-group><article-title>Participation of p53 protein in the cellular response to DNA damage</article-title><source>Cancer Res</source><year>1991</year><volume>51</volume><fpage>6304</fpage><lpage>6311</lpage><pub-id pub-id-type="pmid">1933891</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brugarolas</surname><given-names>J</given-names></name><name><surname>Chandrasekaran</surname><given-names>C</given-names></name><name><surname>Gordon</surname><given-names>JI</given-names></name><name><surname>Beach</surname><given-names>D</given-names></name><name><surname>Jacks</surname><given-names>T</given-names></name><name><surname>Hannon</surname><given-names>GJ</given-names></name></person-group><article-title>Radiation-induced cell cycle arrest compromised by p21 deficiency</article-title><source>Nature</source><year>1995</year><volume>377</volume><fpage>552</fpage><lpage>557</lpage><pub-id pub-id-type="pmid">7566157</pub-id><pub-id pub-id-type="doi">10.1038/377552a0</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Waldman</surname><given-names>T</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name></person-group><article-title>p21 is necessary for the p53-mediated G1 arrest in human cancer cells</article-title><source>Cancer Res</source><year>1995</year><volume>55</volume><fpage>5187</fpage><lpage>5190</lpage><pub-id pub-id-type="pmid">7585571</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Winters</surname><given-names>ZE</given-names></name><name><surname>Ongkeko</surname><given-names>WM</given-names></name><name><surname>Harris</surname><given-names>AL</given-names></name><name><surname>Norbury</surname><given-names>CJ</given-names></name></person-group><article-title>p53 regulates Cdc2 independently of inhibitory phosphorylation of reinforce radiation-induced G2 arrest in human cells</article-title><source>Oncogene</source><year>1998</year><volume>17</volume><fpage>673</fpage><lpage>684</lpage><pub-id pub-id-type="pmid">9715268</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1201991</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dulic</surname><given-names>V</given-names></name><name><surname>Stein</surname><given-names>GH</given-names></name><name><surname>Far</surname><given-names>DF</given-names></name><name><surname>Reed</surname><given-names>SI</given-names></name></person-group><article-title>Nuclear accumulation of p21<sup><italic>Cip</italic>1 </sup>at the onset of mitosis: a role of the G2/M-phase transition</article-title><source>Mol Cell Biol</source><year>1998</year><volume>18</volume><fpage>546</fpage><lpage>557</lpage><pub-id pub-id-type="pmid">9418901</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Poon</surname><given-names>RYC</given-names></name><name><surname>Hunter</surname><given-names>T</given-names></name></person-group><article-title>Expression of a novel form of p21<sup><italic>Cip</italic>1/<italic>Waf</italic>1 </sup>in UV-irradiated and transformed cells</article-title><source>Oncogene</source><year>1998</year><volume>16</volume><fpage>1333</fpage><lpage>1343</lpage><pub-id pub-id-type="pmid">9546435</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1201897</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Orend</surname><given-names>G</given-names></name><name><surname>Hunter</surname><given-names>T</given-names></name><name><surname>Ruoslahti</surname><given-names>E</given-names></name></person-group><article-title>Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21<sup>Cip1 </sup>and p27<sup>Kip1 </sup>in anchorage-independent cells</article-title><source>Oncogene</source><year>1998</year><volume>16</volume><fpage>2575</fpage><lpage>2583</lpage><pub-id pub-id-type="pmid">9632134</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1201791</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barboule</surname><given-names>N</given-names></name><name><surname>Baldin</surname><given-names>V</given-names></name><name><surname>Jozan</surname><given-names>S</given-names></name><name><surname>Vidal</surname><given-names>S</given-names></name><name><surname>Valette</surname><given-names>A</given-names></name></person-group><article-title>Increased level of p21 in human ovarian tumors is associated with increased expression of CDK2, cyclin A and PCNA</article-title><source>Int J Cancer</source><year>1998</year><volume>76</volume><fpage>891</fpage><lpage>896</lpage><pub-id pub-id-type="pmid">9626358</pub-id><pub-id pub-id-type="doi">10.1002/(SICI)1097-0215(19980610)76:6&#x0003c;891::AID-IJC20&#x0003e;3.0.CO;2-4</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Asada</surname><given-names>M</given-names></name><name><surname>Yamada</surname><given-names>T</given-names></name><name><surname>Ichijo</surname><given-names>H</given-names></name><name><surname>Delia</surname><given-names>D</given-names></name><name><surname>Miyazono</surname><given-names>K</given-names></name><name><surname>Fukumuro</surname><given-names>K</given-names></name><name><surname>Mizutani</surname><given-names>S</given-names></name></person-group><article-title>Apoptosis inhibitory activity of cytoplasmic p21<sup>Cip1/WAF1 </sup>in monocytic differentiation</article-title><source>EMBO J</source><year>1999</year><volume>18</volume><fpage>1223</fpage><lpage>1234</lpage><pub-id pub-id-type="pmid">10064589</pub-id><pub-id pub-id-type="doi">10.1093/emboj/18.5.1223</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Winters</surname><given-names>ZE</given-names></name><name><surname>Hunt</surname><given-names>NC</given-names></name><name><surname>Bradburn</surname><given-names>MJ</given-names></name><name><surname>Royds</surname><given-names>JA</given-names></name><name><surname>Turley</surname><given-names>H</given-names></name><name><surname>Harris</surname><given-names>AL</given-names></name><name><surname>Norbury</surname><given-names>CJ</given-names></name></person-group><article-title>Subcellular localization of cyclin B, Cdc2 and p21<sup><italic>WAF1</italic>/<italic>CIPI </italic></sup>in breast cancer: association with prognosis</article-title><source>Eur J Cancer</source><year>2001</year><volume>37</volume><fpage>2405</fpage><lpage>2412</lpage><pub-id pub-id-type="pmid">11720835</pub-id><pub-id pub-id-type="doi">10.1016/S0959-8049(01)00327-6</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mitsuuchi</surname><given-names>Y</given-names></name><name><surname>Johnson</surname><given-names>SW</given-names></name><name><surname>Selvakumaran</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>SJ</given-names></name><name><surname>Hamilton</surname><given-names>TC</given-names></name><name><surname>Testa</surname><given-names>JR</given-names></name></person-group><article-title>The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21<sup>WAF1/CIP1/SDI1 </sup>induced by cisplatin and paclitaxel</article-title><source>Cancer Res</source><year>2000</year><volume>60</volume><fpage>5390</fpage><lpage>5394</lpage><pub-id pub-id-type="pmid">11034077</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>D</given-names></name><name><surname>Jing</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Yao</surname><given-names>J</given-names></name><name><surname>Tan</surname><given-names>M</given-names></name><name><surname>McDonnell</surname><given-names>TJ</given-names></name><name><surname>Hung</surname><given-names>M-C</given-names></name></person-group><article-title>Overexpression of ErbB2 blocks taxol-induced apoptosis by upregulation of p21<sup>Cip1</sup>, which inhibits p34<sup>Cdc2 </sup>kinase</article-title><source>Mol Cell</source><year>1998</year><volume>2</volume><fpage>581</fpage><lpage>591</lpage><pub-id pub-id-type="pmid">9844631</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dupont</surname><given-names>J</given-names></name><name><surname>Karas</surname><given-names>M</given-names></name><name><surname>LeRoith</surname><given-names>D</given-names></name></person-group><article-title>The cyclin dependent kinase inhibitor p21<sup><italic>CIP</italic>/<italic>WAF </italic></sup>is a positive regulator of IGF-1-induced cell proliferation in MCF-7 human breast cancer cells</article-title><source>J Biol Chem</source><year>2003</year><volume>278</volume><fpage>37256</fpage><lpage>37264</lpage><pub-id pub-id-type="pmid">12867429</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M302355200</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>BP</given-names></name><name><surname>Liao</surname><given-names>Y</given-names></name><name><surname>Xia</surname><given-names>W</given-names></name><name><surname>Spohn</surname><given-names>B</given-names></name><name><surname>Lee</surname><given-names>M-H</given-names></name><name><surname>Hung</surname><given-names>M-C</given-names></name></person-group><article-title>Cytoplasmic localisation of p21<sup>Cip1/WAF1 </sup>by Akt-induced phosphorylation in HER-2/neu-overexpressing cells</article-title><source>Nat Cell Biol</source><year>2001</year><volume>3</volume><fpage>245</fpage><lpage>252</lpage><pub-id pub-id-type="pmid">11231573</pub-id><pub-id pub-id-type="doi">10.1038/35060032</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Galea</surname><given-names>MH</given-names></name><name><surname>Blamey</surname><given-names>RW</given-names></name><name><surname>Elston</surname><given-names>CW</given-names></name><name><surname>Ellis</surname><given-names>IO</given-names></name></person-group><article-title>The Nottingham prognostic index in primary breast cancer</article-title><source>Breast Cancer Res Treat</source><year>1992</year><volume>22</volume><fpage>207</fpage><lpage>219</lpage><pub-id pub-id-type="pmid">1391987</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kollias</surname><given-names>J</given-names></name><name><surname>Murphy</surname><given-names>CA</given-names></name><name><surname>Elston</surname><given-names>CW</given-names></name><name><surname>Ellis</surname><given-names>IO</given-names></name><name><surname>Robertson</surname><given-names>JFR</given-names></name><name><surname>Blamey</surname><given-names>RW</given-names></name></person-group><article-title>The prognosis of small primary breast cancers</article-title><source>Eur J Cancer</source><year>1999</year><volume>35</volume><fpage>908</fpage><lpage>912</lpage><pub-id pub-id-type="pmid">10533470</pub-id><pub-id pub-id-type="doi">10.1016/S0959-8049(99)00056-8</pub-id></citation></ref><ref id="B24"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Azzopardi</surname><given-names>J</given-names></name></person-group><source>Problems in Breast Pathology</source><year>1979</year><publisher-name>London: WB Saunders</publisher-name></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Elston</surname><given-names>CW</given-names></name><name><surname>Ellis</surname><given-names>IO</given-names></name></person-group><article-title>Pathological prognostic factors in breast cancer: the value of histological grade in breast cancer: experience from a large study with long-term follow-up</article-title><source>Histopathology</source><year>1991</year><volume>19</volume><fpage>403</fpage><lpage>410</lpage><pub-id pub-id-type="pmid">1757079</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rhodes</surname><given-names>A</given-names></name><name><surname>Jasani</surname><given-names>B</given-names></name><name><surname>Anderson</surname><given-names>E</given-names></name><name><surname>Dodson</surname><given-names>AR</given-names></name><name><surname>Balaton</surname><given-names>AJ</given-names></name></person-group><article-title>Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries</article-title><source>Am J Clin Pathol</source><year>2002</year><volume>118</volume><fpage>408</fpage><lpage>417</lpage><pub-id pub-id-type="pmid">12219783</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Buuren</surname><given-names>S</given-names></name><name><surname>Boshuizen</surname><given-names>HC</given-names></name><name><surname>Knook</surname><given-names>DL</given-names></name></person-group><article-title>Multiple imputation of missing blood pressure covariates in survival analysis</article-title><source>Stat Med</source><year>1999</year><volume>18</volume><fpage>681</fpage><lpage>694</lpage><pub-id pub-id-type="pmid">10204197</pub-id><pub-id pub-id-type="doi">10.1002/(SICI)1097-0258(19990330)18:6&#x0003c;681::AID-SIM71&#x0003e;3.3.CO;2-I</pub-id></citation></ref><ref id="B28"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Van Buuren</surname><given-names>S</given-names></name><name><surname>Oudshoorn</surname><given-names>CGM</given-names></name></person-group><source>Multiple imputation by chained equations: MICE 10 users manual</source><publisher-name>Leiden, The Netherlands: TNO Institute for Prevention and Health</publisher-name><ext-link ext-link-type="uri" xlink:href="http://web.inter.nl.net/users/S.van.Buuren/mi/docs/Manual.pdf"/></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nicholson</surname><given-names>RI</given-names></name><name><surname>Hutcheson</surname><given-names>IR</given-names></name><name><surname>Harper</surname><given-names>ME</given-names></name><name><surname>Knowlden</surname><given-names>JM</given-names></name><name><surname>Barrow</surname><given-names>D</given-names></name><name><surname>McClelland</surname><given-names>RA</given-names></name><name><surname>Jones</surname><given-names>HE</given-names></name><name><surname>Wakeling</surname><given-names>AE</given-names></name><name><surname>Gee</surname><given-names>JMW</given-names></name></person-group><article-title>Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer</article-title><source>Endocr Relat Cancer</source><year>2001</year><volume>8</volume><fpage>175</fpage><lpage>182</lpage><pub-id pub-id-type="pmid">11566608</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dowsett</surname><given-names>M</given-names></name></person-group><article-title>Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer</article-title><source>Endocr Relat Cancer</source><year>2001</year><volume>8</volume><fpage>191</fpage><lpage>195</lpage><pub-id pub-id-type="pmid">11566610</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>BP</given-names></name><name><surname>Liao</surname><given-names>Y</given-names></name><name><surname>Xia</surname><given-names>X</given-names></name><name><surname>Zou</surname><given-names>Y</given-names></name><name><surname>Spohn</surname><given-names>B</given-names></name><name><surname>Hung</surname><given-names>M-C</given-names></name></person-group><article-title>HER-2/ neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation</article-title><source>Nat Cell Biol</source><year>2001</year><volume>3</volume><fpage>973</fpage><lpage>982</lpage><pub-id pub-id-type="pmid">11715018</pub-id><pub-id pub-id-type="doi">10.1038/ncb1101-973</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dowsett</surname><given-names>M</given-names></name><name><surname>Bartlett</surname><given-names>J</given-names></name><name><surname>Ellis</surname><given-names>IO</given-names></name><name><surname>Salter</surname><given-names>J</given-names></name><name><surname>Hills</surname><given-names>M</given-names></name><name><surname>Mallon</surname><given-names>E</given-names></name><name><surname>Watters</surname><given-names>AD</given-names></name><name><surname>Cooke</surname><given-names>T</given-names></name><name><surname>Paish</surname><given-names>C</given-names></name><name><surname>Wencyk</surname><given-names>PM</given-names></name><name><surname>Pinder</surname><given-names>SE</given-names></name></person-group><article-title>Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres</article-title><source>J Pathol</source><year>2003</year><volume>199</volume><fpage>418</fpage><lpage>423</lpage><pub-id pub-id-type="pmid">12635131</pub-id><pub-id pub-id-type="doi">10.1002/path.1313</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barbareschi</surname><given-names>M</given-names></name><name><surname>Doglioni</surname><given-names>C</given-names></name><name><surname>Veronese</surname><given-names>S</given-names></name><name><surname>Bonzanini</surname><given-names>M</given-names></name><name><surname>Dalla Palma</surname><given-names>P</given-names></name><name><surname>Harris</surname><given-names>AL</given-names></name><name><surname>Caffo</surname><given-names>O</given-names></name></person-group><article-title>p21<sup><italic>WAF1 </italic></sup>and p53 immunohistochemical expression in breast carcinoma may predict therapeutic response to adjuvant treatment</article-title><source>Eur J Cancer</source><year>1996</year><volume>32</volume><fpage>2182</fpage><lpage>2183</lpage><pub-id pub-id-type="doi">10.1016/S0959-8049(96)00222-5</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Diab</surname><given-names>SG</given-names></name><name><surname>Yu</surname><given-names>YY</given-names></name><name><surname>Hilsenbeck</surname><given-names>SG</given-names></name><name><surname>Allred</surname><given-names>DC</given-names></name><name><surname>Elledge</surname><given-names>RM</given-names></name></person-group><article-title>WAF1/CIP1 protein expression in human breast tumours</article-title><source>Breast Cancer Res Treat</source><year>1997</year><volume>43</volume><fpage>99</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">9131264</pub-id><pub-id pub-id-type="doi">10.1023/A:1005752829260</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pellikainen</surname><given-names>MJ</given-names></name><name><surname>Pekola</surname><given-names>TT</given-names></name><name><surname>Ropponen</surname><given-names>KM</given-names></name><name><surname>Kataja</surname><given-names>VV</given-names></name><name><surname>Kellokoski</surname><given-names>JK</given-names></name><name><surname>Eskelinen</surname><given-names>MJ</given-names></name><name><surname>Kosma</surname><given-names>V-M</given-names></name></person-group><article-title>p21WAF1 expression in invasive breast cancer and its association with p53, AP-2, cell proliferation, and prognosis</article-title><source>J Clin Pathol</source><year>2003</year><volume>56</volume><fpage>214</fpage><lpage>220</lpage><pub-id pub-id-type="pmid">12610102</pub-id><pub-id pub-id-type="doi">10.1136/jcp.56.3.214</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>G&#x000f6;hring</surname><given-names>U-J</given-names></name><name><surname>Bersch</surname><given-names>A</given-names></name><name><surname>Becker</surname><given-names>M</given-names></name><name><surname>Neuhaus</surname><given-names>W</given-names></name><name><surname>Sch&#x000f6;ndorf</surname><given-names>T</given-names></name></person-group><article-title>p21waf correlates with DNA replication but not with prognosis in invasive breast cancer</article-title><source>J Clin Pathol</source><year>2001</year><volume>54</volume><fpage>866</fpage><lpage>870</lpage><pub-id pub-id-type="pmid">11684722</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McClelland</surname><given-names>RA</given-names></name><name><surname>Gee</surname><given-names>JM</given-names></name><name><surname>O'Sullivan</surname><given-names>L</given-names></name></person-group><article-title>p21 (WAF1) expression and endocrine response in breast cancer</article-title><source>J Pathol</source><year>1999</year><volume>188</volume><fpage>126</fpage><lpage>132</lpage><pub-id pub-id-type="pmid">10398154</pub-id><pub-id pub-id-type="doi">10.1002/(SICI)1096-9896(199906)188:2&#x0003c;126::AID-PATH340&#x0003e;3.3.CO;2-F</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leonard</surname><given-names>DS</given-names></name><name><surname>Hill</surname><given-names>ADK</given-names></name><name><surname>Kelly</surname><given-names>L</given-names></name><name><surname>Dijkstra</surname><given-names>B</given-names></name><name><surname>McDermott</surname><given-names>E</given-names></name><name><surname>O'Higgins</surname><given-names>NJ</given-names></name></person-group><article-title>Anti-human epidermal growth factor receptor 2 monoclonal antibody therapy for breast cancer</article-title><source>Br J Surg</source><year>2002</year><volume>89</volume><fpage>262</fpage><lpage>271</lpage><pub-id pub-id-type="pmid">11872048</pub-id><pub-id pub-id-type="doi">10.1046/j.0007-1323.2001.02022.x</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Zi</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Mascarenhas</surname><given-names>D</given-names></name><name><surname>Pollak</surname><given-names>M</given-names></name></person-group><article-title>Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (herceptin)</article-title><source>J Natl Cancer Inst</source><year>2001</year><volume>93</volume><fpage>1852</fpage><lpage>1857</lpage><pub-id pub-id-type="pmid">11752009</pub-id><pub-id pub-id-type="doi">10.1093/jnci/93.24.1852</pub-id></citation></ref></ref-list><sec sec-type="display-objects"><title>Figures and Tables</title><fig position="float" id="F1"><label>Figure 1</label><caption><p>Examples of HER-2 and p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>immunoreactivity in infiltrating ductal carcinoma of the breast. Immunostaining was performed as described in Materials and methods, and nuclei were counterstained with haematoxylin. <bold>(a) </bold>A tumour showing HER-2 overexpression, with <bold>(b) </bold>a concomitant predominance of cytoplasmic p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1</sup>staining and minimal or no nuclear p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>expression. <bold>(c) </bold>A HER-2-negative tumour, with <bold>(d) </bold>a predominance of nuclear p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>expression compared with cytoplasmic p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1</sup>, which was proportionately less on intensity distribution scoring in 10 fields. Insets in panels (b) and (d) show higher-power views of the same fields. Magnification &#x000d7; 3&#x02013;4.</p></caption><graphic xlink:href="bcr654-1"/></fig><fig position="float" id="F2"><label>Figure 2</label><caption><p>Relationship between HER-2 and p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>localisation. Scatter plots according to HER-2 status and the subcellular localisation of p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>measured as an intensity distribution score (IDS). HER-2 staining was analysed as described in Materials and methods. <bold>(a)</bold>Distribution of nuclear p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>IDS and medians according to HER-2-negative and HER-2-positive breast cancers, with patient numbers shown. <bold>(b) </bold>Cytoplasmic p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>IDS and medians according to HER-2 status, and numbers of patients. Of the 67 patients, nuclear p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>was not evaluable in four patients, or in the cytoplasm in six cases. <italic>P </italic>values indicate significance.</p></caption><graphic xlink:href="bcr654-2"/></fig><fig position="float" id="F3"><label>Figure 3</label><caption><p>Relationship between HER-2 and prognosis in 67 patients using the log-rank test. <bold>(a) </bold>Overall survival curves according to HER-2 status, classified as negative or positive according to Materials and methods. <bold>(b) </bold>Relapse-free survival curves according to HER-2 expression. Significant <italic>P </italic>values are indicated in bold.</p></caption><graphic xlink:href="bcr654-3"/></fig><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Clinicopathological variables according to c-erbB2 status</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center">HER-2-negative</td><td align="center">HER-2-positive</td><td align="center"><italic>P</italic></td><td align="center">Overall</td></tr></thead><tbody><tr><td align="left">Total</td><td align="center">54</td><td align="center">13</td><td></td><td align="center">67</td></tr><tr><td align="left">Oestrogen receptor status</td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;&#x02264; 10 fmol/mg</td><td align="center">25</td><td align="center">10</td><td align="center">0.05*</td><td align="center">35</td></tr><tr><td align="left">&#x02003;&#x0003e; 10 fmol/mg</td><td align="center">29</td><td align="center">3</td><td></td><td align="center">32</td></tr><tr><td align="left">Node status</td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Negative</td><td align="center">36</td><td align="center">8</td><td align="center">0.73</td><td align="center">44</td></tr><tr><td align="left">&#x02003;Positive</td><td align="center">18</td><td align="center">5</td><td></td><td align="center">23</td></tr><tr><td align="left">Histologic grade</td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Grade I</td><td align="center">4</td><td align="center">0</td><td align="center">0.48</td><td align="center">4</td></tr><tr><td align="left">&#x02003;Grade II</td><td align="center">17</td><td align="center">5</td><td></td><td align="center">22</td></tr><tr><td align="left">&#x02003;Grade III</td><td align="center">22</td><td align="center">7</td><td></td><td align="center">29</td></tr><tr><td align="left">&#x02003;'Other'</td><td align="center">11</td><td align="center">1</td><td></td><td align="center">12</td></tr><tr><td align="left">Nottingham Prognostic Index</td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;GPG score &#x02264; 3.4</td><td align="center">4</td><td align="center">1</td><td align="center">0.61</td><td align="center">6</td></tr><tr><td align="left">&#x02003;MPG score 3.4&#x02013;5.4</td><td align="center">28</td><td align="center">8</td><td></td><td align="center">40</td></tr><tr><td align="left">&#x02003;PPG score &#x0003e; 5.4</td><td align="center">7</td><td align="center">3</td><td></td><td align="center">10</td></tr><tr><td align="left">Age</td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;&#x0003c; 50 years</td><td align="center">19</td><td align="center">8</td><td></td><td align="center">28</td></tr><tr><td align="left">&#x02003;&#x02265; 50 years</td><td align="center">35</td><td align="center">5</td><td></td><td align="center">39</td></tr><tr><td align="left">&#x02003;Median (range)</td><td align="center">56 (32&#x02013;80)</td><td align="center">46 (37&#x02013;67)</td><td align="center">0.03*</td><td align="center">55 (32&#x02013;80)</td></tr><tr><td align="left">Tumour size</td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;&#x02264; 2 cm</td><td align="center">15</td><td align="center">4</td><td></td><td align="center">19</td></tr><tr><td align="left">&#x02003;&#x0003e; 2 cm</td><td align="center">39</td><td align="center">9</td><td></td><td align="center">48</td></tr><tr><td align="left">&#x02003;Median (range)</td><td align="center">2.5 (1&#x02013;5.5)</td><td align="center">2.6 (1&#x02013;5.3)</td><td align="center">0.76</td><td align="center">2.5 (1&#x02013;5.5)</td></tr></tbody></table><table-wrap-foot><p>GPG, good prognostic group; MPG, moderate prognostic group; PPG, poor prognostic group. *Relationship reached significance (<italic>P </italic>&#x02264; 0.05).</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Relationships between HER-2 and p21<sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup><bold>localisation and overall survival/relapse-free survival</bold></p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td></td><td align="center" colspan="3">Univariate analysis</td><td align="center" colspan="3">Multivariate analysis</td></tr><tr><td></td><td align="center">Number of patients</td><td align="center">Hazard ratio per 10 IDS units for p21</td><td align="center">95% confidence interval</td><td align="center"><italic>P</italic></td><td align="center">Hazard ratio per 10 IDS units for p21</td><td align="center">95% confidence interval</td><td align="center"><italic>P</italic></td></tr></thead><tbody><tr><td align="left">Overall survival</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;p21</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;p21 nucleus</td><td align="center">64</td><td align="center">0.96</td><td align="center">0.77, 1.19</td><td align="center">0.70</td><td align="center">0.96</td><td align="center">0.75, 1.22</td><td align="center">0.73</td></tr><tr><td align="left">&#x02003;p21 cytoplasm</td><td align="center">63</td><td align="center">1.12*</td><td align="center">1.01, 1.25</td><td align="center">0.03*</td><td align="center">1.15*</td><td align="center">1.03, 1.28</td><td align="center">0.01*</td></tr><tr><td align="left">&#x02003;HER-2 (2+/3+ versus 0/1+)</td><td align="center">63</td><td align="center">2.26*</td><td align="center">1.00, 5.27</td><td align="center">0.05*</td><td align="center">3.14*</td><td align="center">1.15, 8.64</td><td align="center">0.03*</td></tr><tr><td align="left">Relapse-free survival</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;p21</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;p21 nucleus</td><td align="center">64</td><td align="center">1.01</td><td align="center">0.84, 1.22</td><td align="center">0.89</td><td align="center">1.03</td><td align="center">0.84, 1.25</td><td align="center">0.80</td></tr><tr><td align="left">&#x02003;p21 cytoplasm</td><td align="center">63</td><td align="center">1.12*</td><td align="center">1.01, 1.24</td><td align="center">0.03*</td><td align="center">1.15*</td><td align="center">1.02, 1.28</td><td align="center">0.02*</td></tr><tr><td align="left">&#x02003;HER-2 (2+/3+ versus 0/1+)</td><td align="center">63</td><td align="center">2.60*</td><td align="center">1.19, 5.71</td><td align="center">0.02*</td><td align="center">4.08*</td><td align="center">1.60, 10.39</td><td align="center">0.003*</td></tr></tbody></table><table-wrap-foot><p>Hazard ratios, confidence intervals and <italic>P </italic>values are given for the results of both the univariate analyses and the multivariate analyses. For univariate and multivariate analyses, the hazard ratio is given for nuclear and cytoplasmic p21 <sup><italic>WAF</italic>1/<italic>CIP</italic>1 </sup>per 10 unit increase in intensity distribution score (IDS), along with the 95% confidence interval. The hazard ratio and confidence interval for HER-2 relates to 2+/3+ versus 0/1+. Patients with ductal, lobular or 'mixed' cancer were included where the marker data was available. The multivariate analysis is adjusted for the Nottingham Prognostic Index (NPI) (nodes, grade and size) and for treatment (tamoxifen/chemotherapy/no treatment), with the NPI based on imputed grades and tumour sizes where the relevant data were missing as described in the statistical methods. *Relationship reached significance (<italic>P </italic>&#x0003c; 0.05).</p></table-wrap-foot></table-wrap></sec></back></article> 